PINK - ETF AI Analysis
Top Page
Simplify Health Care ETF (PINK)
Rating:64Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered steady gains over the past month, three months, and year-to-date, showing positive momentum.
Leading Health Care Companies
Several top holdings like UnitedHealth, Eli Lilly, Johnson & Johnson, AbbVie, and Biohaven have shown strong performance, helping support the fund’s returns.
Focused Health Care Exposure
The fund’s heavy tilt toward the health care sector gives investors targeted exposure to a key defensive area of the market.
Negative Factors
Sector Concentration Risk
With most assets in health care, the ETF could be hit hard if this single sector faces regulatory changes or industry-specific challenges.
High Weight in a Weak Holding
A sizable position in PureCycle Technologies has shown weak performance, which can drag on overall returns if the stock continues to struggle.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are used to cover fees instead of going to investors.
PINK vs. SPDR S&P 500 ETF (SPY)
AUM363.04M
RegionNorth America
Expense Ratio0.51%
Beta0.65
IssuerSimplify
Inception DateOct 07, 2021
Dividend Yield0.64%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume73,141
30 Day Avg. Volume88,568
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
47.62Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering53
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PINK Summary
The Simplify Health Care ETF (PINK) is a fund that focuses on the health care theme rather than tracking a specific index. It invests mainly in U.S. health care companies across areas like biotech, drug makers, medical devices, and health insurers. Well-known holdings include Johnson & Johnson and Eli Lilly. Someone might invest in PINK to tap into long-term growth from medical innovation and an aging population, while also getting diversification across many health care names. A key risk is that it is heavily concentrated in the health care sector, so its price can rise or fall sharply with news and trends in that industry.
How much will it cost me?The Simplify Health Care ETF (PINK) has an expense ratio of 0.5%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specific sector like health care, which requires more research and expertise. It’s designed to give investors targeted exposure to innovative health care companies.
What would affect this ETF?The Simplify Health Care ETF (PINK) could benefit from advancements in biotechnology and pharmaceuticals, as well as increased demand for health care services driven by aging populations and global health awareness. However, it may face challenges from regulatory changes, pricing pressures in the pharmaceutical industry, and potential economic downturns that could impact consumer spending on health care. Its strong U.S. focus and top holdings in companies like UnitedHealth and AbbVie position it well for growth but also expose it to risks tied to U.S. health care policies.
PINK Top 10 Holdings
PINK is a pure play on U.S. health care, with a heavy tilt toward big drugmakers and insurers. Eli Lilly has been a steady but not spectacular engine, while Humana and Johnson & Johnson are helping power the fund with rising share prices and solid execution. Thermo Fisher and AbbVie add more momentum, benefiting from strong demand and robust pipelines. On the flip side, PureCycle Technologies is dragging the portfolio, its struggles standing out in an otherwise healthy lineup. Overall, performance is driven by a concentrated mix of large-cap pharma and managed care names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 9.82% | $35.73M | $1.07T | 51.05% | 72 Outperform | |
| Humana | 7.09% | $25.81M | $46.20B | 45.18% | 69 Neutral | |
| Thermo Fisher | 5.49% | $19.96M | $239.76B | 36.84% | 72 Outperform | |
| PureCycle Technologies | 5.36% | $19.50M | $1.11B | -58.68% | 38 Underperform | |
| Johnson & Johnson | 5.07% | $18.43M | $644.12B | 55.16% | 78 Outperform | |
| AbbVie | 4.80% | $17.48M | $463.89B | 18.93% | 66 Neutral | |
| UnitedHealth | 4.35% | $15.84M | $336.83B | 11.44% | 72 Outperform | |
| United Therapeutics | 4.35% | $15.82M | $21.38B | 21.32% | 79 Outperform | |
| Avantor | 4.34% | $15.79M | $10.56B | 23.33% | 48 Neutral | |
| Warby Parker | 4.01% | $14.58M | $2.91B | -14.68% | 60 Neutral |
PINK Technical Analysis
Negative
―
Price Trends
39.37
Negative
38.28
Positive
36.98
Positive
Market Momentum
-0.20
Positive
44.56
Neutral
31.41
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PINK, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 39.38, equal to the 50-day MA of 39.37, and equal to the 200-day MA of 36.98, indicating a neutral trend. The MACD of -0.20 indicates Positive momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 31.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PINK.
PINK Peer Comparison
Comparison Results
Performance Comparison
PINK
Simplify Health Care ETF
38.82
7.66
24.58%
GTOP
Goldman Sachs Technology Opportunities ETF
―
―
―
IETC
iShares Evolved US Technology ETF
―
―
―
IYRI
NEOS Real Estate High Income ETF
―
―
―
WELD
Tema U.S. Manufacturing & Reshoring ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents